newsfilter
← Latest News
Business Wire·

HeartBeam Awarded New U.S. Patent Expanding Acoustic Sensing and Fluid Monitoring Capabilities of Its Cable-Free ECG Device

BEAT
  • HeartBeam, Inc. received U.S. patent allowance for integrating acoustic sensing & thoracic impedance measurement into its credit card-sized ECG hardware.
  • Acoustic sensors enable the device to function as a "digital stethoscope" to assess heart valve function by capturing sounds from mitral & tricuspid valves.
  • Thoracic impedance capability allows non-invasive monitoring of fluid accumulation in the chest to support heart failure detection without surgical procedures.
  • The patent protects the integration of these multi-modal sensors into the device's foldable arms & chest electrodes, positioning the platform for structural heart disease applications.
  • Heart failure affects approximately 6.7 million U.S. adults & costs an estimated $30,000 per patient annually, with earlier fluid detection potentially reducing hospitalizations.
  • HeartBeam now holds 26 issued patents worldwide, reinforcing its intellectual property moat across signal acquisition, algorithms, diagnostics, & hardware.
  • Acoustic sensing & thoracic impedance capabilities remain investigational & are not currently FDA cleared, unlike the device's existing ECG synthesis software cleared for arrhythmia assessment in December 2025.
  • The company aims to use this multi-modal platform to enable remote cardiac care, improve patient outcomes, & support future reimbursement pathways.